| Name | Title | Contact Details |
|---|---|---|
Arya Sadeghi |
Senior Counsel | Profile |
Laura Brake |
Associate General Counsel | Profile |
Matt Bennett |
Head of Sales, Teliso-V | Profile |
Paul Hammond |
Associate General Counsel | Profile |
Ying Deng |
Senior Associate General Counsel, Global | Profile |
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
TransparentRx is a fiduciary and transparent PBM company that specializes in providing effective solutions for self-funded employer groups, health plans, TPAs, business coalitions and government entities.
Powered by its artificial intelligence software platform, nferX, nference`s mission is to synthesize the exponentially growing biomedical knowledge. nferX uses state-of-the-art neural networks (shallow and deep learning models) for real-time, automated extraction of knowledge from the commercial, scientific and regulatory body of literature.
ABO Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.